title: STI571 (GLIVEC) induced hematologic, cytogenetic and molecular remission in a cml patient relapsing with accelerated phase after allogeneic stem cell transplantation.
authors.affiliation: Division of Haematology with Bone Marrow Transplantation, University of Catania, Italy. ugo.consoli@tin.it
authors.forename: Ugo
authors.initials: U
authors.lastname: Consoli
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Milone
authors.forename: Giulia
authors.initials: G
authors.lastname: Guido
authors.forename: Carla
authors.initials: C
authors.lastname: Consoli
authors.forename: Giuseppe A
authors.initials: GA
authors.lastname: Palumbo
authors.forename: Rosario
authors.initials: R
authors.lastname: Giustolisi
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D001549:Benzamides; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D012074:Remission Induction / Q000379:methods; D016879:Salvage Therapy; D014184:Transplantation, Homologous
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate